Verónica González‐Calle
- Hematology top 5%
- Multiple Myeloma Research and Treatments 35
-
- Myeloproliferative Neoplasms: Diagnosis and Treatment 7
- Chronic Lymphocytic Leukemia Research 6
-
- Peptidase Inhibition and Analysis 9
- Toxicology top 10%
-
- Amyloidosis: Diagnosis, Treatment, Outcomes 12
- Protein Degradation and Inhibitors 11
-
- Lymphoma Diagnosis and Treatment 6
-
- Alzheimer's disease research and treatments 4
- Co-authors
- Li TangYuesheng ZhangMaría‐Victoria MateosRamón García‐SánzNoemí PuigNorma C. GutiérrezEinar M. SigurdssonFernando Escalante
- Cited by
- HematologyGeneticsOncology
- Partner nations
- SpainUnited StatesChile
In The Last Decade
Verónica González‐Calle
64 papers receiving 659 citations
Peers
Comparison fields: 5 of 86
- Hematology 224
- Genetics 68
- Oncology 174
- Toxicology 21
- Molecular Biology 367
Countries citing papers authored by Verónica González‐Calle
This map shows the geographic impact of Verónica González‐Calle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Verónica González‐Calle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Verónica González‐Calle more than expected).
Fields of papers citing papers by Verónica González‐Calle
This network shows the impact of papers produced by Verónica González‐Calle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Verónica González‐Calle. The network helps show where Verónica González‐Calle may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Verónica González‐Calle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2023 | 4 | |
| 3 | 2023 | 2 | |
| 4 | 2023 | 36 | |
| 5 | 2023 | 8 | |
| 6 | 2021 | 2 | |
| 7 | 2020 | 7 | |
| 8 | 2020 | 2 | |
| 9 | 2019 | 10 | |
| 10 | 2019 | 22 | |
| 11 | 2018 | 9 | |
| 12 | 2018 | 5 | |
| 13 | 2018 | 24 | |
| 14 | 2017 | 27 | |
| 15 | 2017 | 19 | |
| 16 | 2017 | 5 | |
| 17 | 2016 | 0 | |
| 18 | 2015 | 23 | |
| 19 | 2012 | 9 | |
| 20 | 2007 | 37 |
About Verónica González‐Calle
Verónica González‐Calle is a scholar working on Hematology, Genetics and Oncology, having authored 70 papers that have together received 677 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (35 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (12 papers), Protein Degradation and Inhibitors (11 papers), Peptidase Inhibition and Analysis (9 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Alzheimer's disease research and treatments (4 papers). The work is most often cited by research in Hematology (224 citations), Genetics (68 citations) and Oncology (174 citations). Verónica González‐Calle has collaborated with scholars based in Spain, United States and Chile. Frequent co-authors include Li Tang, Yuesheng Zhang, María‐Victoria Mateos, Ramón García‐Sánz, Noemí Puig, Norma C. Gutiérrez, Einar M. Sigurdsson, Fernando Escalante, Cristina Jiménez and Carmen Chillón. Their work appears in journals such as Blood, Cancers, HemaSphere, British Journal of Haematology and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.